Axcentua Pharmaceuticals
Karolinska Institute Science Park
Nobels Alle 10
14157 Stockholm


Project partner until March 31, 2013

Institute presentation

Axcentua Pharmaceuticals AB is an early clinical stage pharmaceutical company located at the Karolinska Institute Science Park, Stockholm, with an innovative approach to drug discovery and development of novel therapeutics. The focus of Axcentua is to develop proprietary small-molecule drugs derived from natural compounds .The core business idea and competitive advantage is to decrease drug development times and to reduce the risk for failure in pre-clinical and clinical development by using natural compounds with well documented effects using crystal screening and polymorph screens, patentable prescription drugs are rapidly developed from natural compounds.

Its first product, AXP107-11, is currently in Phase Ib clinical trials for the treatment of pancreatic cancer at the Karolinska University Hospital in Huddinge, Sweden.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Until you give your consent, only those cookies necessary to maintain the website's functionality are active. When you choose "OK", so called third-party non-functional cookies (e.g. GDPR-conform Google Analytics) may also become active. Please be aware that the website's functionality may be restricted if you choose "DECLINE". You can revoke your choice at any time by clearing your browser cache/history and updating your selection. Please also view our privacy policy.